Loading patent…
OwnerStephen Hunter Diaz, Theodore L Parker +3inventors
InventorsStephen Hunter Diaz, Theodore L Parker, John F Shanley, Brett Trauthen, Frank Litvack
Estimating the term…
Abstract of the Disclosure A method for decreasing the level of restenosis following a stent placement medical intervention involves the continuous administration of a dose of an anti-restenotic agent , such as paclitaxel, from the stent to vascular tissue in need of treatment in a controlled, extended ,and substantially linear drug release profile. The method of substantially linear extended release increases the therapeutic effectiveness of administration of a given dosage. In one example, a method of reducing restenosis includes delivering paclitaxel from a stent to an artery at a minimum release rate of 1 percent of the total dosage of paclitaxel on the stent per day throughout an entire administration period from the time of implantation of the stent until the time that substantially all the paclitaxel is released from the stent.
A method of reducing restenosis comprising:
A method of reducing restenosis comprising:
A method of reducing restenosis comprising:
A method of reducing restenosis comprising:
The method of Claim 27, wherein the administration period is about 20 to about 40 days from the date of implantation.
A method of treating a patient comprising:
The method of Claim 35, wherein the administration period is about 20 to about 40 days from the date of implantation.
A stent for reducing restenosis comprising:
The stent of Claim 40, wherein the administration period is about 20 to about 40 days from the date of implantation.
Dependencies are inferred from the claim text.